Maria Daniela Hurtado Andrade, an obesity specialist at the Mayo Clinic in Jacksonville, Florida, says she doesnt recommend oral compounded GLP-1 medications to her patients
What happens to my GLP-1 coverage when I turn 65 and switch to UnitedHealthcare Medicare Advantage
This story is done in collaboration with First Check, which is the health journalism vertical of DataLEADS
In many APAC markets where healthcare spending is largely out of pocket, adoption tends to be slower, explains FMCG consultant Veena Giridhar-Gopal, adding that the demand profile has traditionally differed from that of western markets
Foundayo (orforglipron) is Eli Lilly's small-molecule oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related condition
Liver disease in heart failure with preserved ejection fraction The relationship between heart failure (HF) and liver disease is characterized by bidirectional interactions where one condition exacerbates the other
